A PHASE III, RANDOMIZED, OPEN-LABEL COMPARISON OF LOPINAVIR/RITONAVIR PLUS EF

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 中心，不一定是研究者的机构。 主要目标是： 1.比较3个治疗组之间的至病毒学失败时间：LPV/r + EFV、LPV/r + d4 T XR（或ZDV）+3 TC和EFV + d4 T XR（或ZDV）+3 TC。 (See病毒学失败的定义见第3.5节。） 2.比较3个治疗组之间的至方案完成时间：LPV/r + EFV、LPV/r + d4 T XR（或ZDV）+3 TC和EFV + d4 T XR（或ZDV）+3 TC。 方案完成将定义为病毒学失败或初始随机化治疗方案任何组分的毒性相关停药。 病毒学失败和方案完成的定义见第3.5节和第3.6节。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary objectives are: 1. To compare the time to virologic failure pairwise between the three treatment groups: LPV/r plus EFV, LPV/r plus d4T XR (or ZDV) plus 3TC, and EFV plus d4T XR (or ZDV) plus 3TC. (See Section 3.5 for definition of virologic failure.) 2. To compare the time to regimen completion pairwise between the three treatment groups: LPV/r plus EFV, LPV/r plus d4T XR (or ZDV) plus 3TC, and EFV plus d4T XR (or ZDV) plus 3TC. Regimen completion will be defined as either virologic failure or toxicity-related discontinuation of any component of the initial randomized treatment regimen. See sections 3.5 and 3.6 for definition of virologic failure and regimen completion.